Bimekizumab shows significant psoriasis skin clearance in phase 3 trial

874985

Sumary of Bimekizumab shows significant psoriasis skin clearance in phase 3 trial:

  • Warren reports he receives research grants and/or consulting fees from AbbVie, Almirall, Amgen, Arena, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi and UCB Pharma….

Want to know more click here go to health news source.

From -

Close

Languages